Search
Selected Filter
Filter Results
Displaying 11–20 of 315 research results
-
Mar 27, 2024
Nanoscope Plans to Apply for FDA Approval for its Optogenetic Therapy
The company reported positive two-year results for its Phase 2 clinical trial of MCO-010.
-
Mar 26, 2024
Opus Reports Vision Improvements for Patients in LCA5 Gene Therapy Clinical Trial
The company plans to administer a higher dose of the emerging gene therapy to the next group of patients.
-
Feb 21, 2024
jCyte Announces Plans to Launch Phase 3 Clinical Trial of Cell Therapy for RP
Known as retinal progenitors, the company’s jCells® are designed to preserve photoreceptors in people with retinitis pigmentosa (RP) and other retinal diseases.
-
Feb 9, 2024
The company plans to begin a Phase 2/3 clinical trial for the treatment during the first half of 2024.
-
Feb 1, 2024
Ascidian to Launch Clinical Trial for Stargardt Disease RNA Editing Therapy
ACDN-01 is the only genetic medicine entering clinical development for Stargardt disease.
-
Dec 11, 2023
Known as antisense oligonucleotides, the treatments performed encouragingly in ProQR’s clinical trials
-
Nov 8, 2023
Kiora Reports Vision Restoration in Phase 1/2 Clinical Trial for Photoswitch Therapy
The company’s molecule is designed to restore some vision to people with ultra-low or no vision caused by advanced retinitis pigmentosa and other retinal diseases.
-
Nov 2, 2023
New Report: Vitamin A Supplementation Provides No Vision Benefit to RP Patients
The report also concludes that vitamin E supplementation accelerates vision loss for RP patients
-
Sep 18, 2023
Ocugen Reports Updated Results for Clinical Trial of Modifier Gene Therapy
The company is also launching modifier gene therapy clinical trials for GA and Stargardt disease
-
Sep 7, 2023
First Patient Dosed in LCA5 Gene Therapy Clinical Trial Launched by Opus Genetics
Opus was established by the RD Fund, the Foundation’s venture philanthropy arm